Prenosis Secures $20M BARDA Contract and Series A Funding to Enhance Diagnostics and Therapeutics

Prenosis, a pioneering company specializing in biology-based technologies, has reached significant milestones with the announcement of a new $20 million contract from the Biomedical Advanced Research and Development Authority (BARDA) along with a successful $20 million Series A financing round. These developments mark a major step forward in Prenosis' mission to transform healthcare through advanced integrated diagnostics and therapeutics.

Funding and Its Impact

The recent funding includes contributions from private investors such as PACE Healthcare Capital, UC Investments, and Labcorp Venture Fund, among others. This financial boost is intended to propel the commercial delivery of Prenosis’s AI-based diagnostic tools, enhance clinical trial enrollment processes, develop and validate algorithms, and advance necessary regulatory protocols. Furthermore, the funding will expand Prenosis’ precision medicine platform to address several critical care conditions like sepsis, pneumonia, acute heart failure (AHF), acute respiratory distress syndrome (ARDS), and acute kidney injury (AKI).

CEO Insights

Bobby Reddy, Jr., the CEO, remarked on the significance of these investments, stating, "Because of these investments, we are well-positioned to advance the development of biology-driven solutions that can transform outcomes for patients facing the most critical conditions." He emphasized the company's commitment to delivering personalized healthcare solutions tailored to individual patients rather than using a one-size-fits-all model.

Innovative Diagnostic Tools

One of the standout products from Prenosis is the Sepsis ImmunoScore®, which is significant as it is the first FDA-authorized AI diagnostic tool specifically for sepsis. This diagnostic tool aims to assist healthcare providers in diagnosing sepsis in a timely manner—a critical aspect since sepsis accounts for more annual deaths than all cancers combined. Julia Monfrini Peev, Managing Partner at PACE Healthcare Capital, highlighted the importance of the Sepsis ImmunoScore®, saying, "Sepsis kills more people annually than all cancers combined. It is difficult to diagnose and treat in a timely manner, plaguing patients, providers, and payers."

BARDA’s Contribution

The $20 million contract from BARDA, awarded under its Type to Treat Program, is particularly promising. It will fund pivotal studies aimed at catalyzing the development of a comprehensive precision medicine platform. A significant aspect of this project includes a randomized controlled trial that will involve around 800 patients suffering from severe respiratory infections. This trial will assess the efficacy of corticosteroids in treating these patients while evaluating the tool's effectiveness in identifying those most likely to benefit from this therapy.

Expansion of Clinical Networks

Prenosis plans to integrate its Immunix™ platform into approximately 40 of the foremost academic medical centers across the United States. This initiative is aimed at establishing a first-of-its-kind precision medicine clinical trial network, which will facilitate the swift identification of patients with specific biological characteristics essential for therapeutic trials.

Carlos Lopez-Espina, SVP of Research and Development at Prenosis, expressed excitement over this innovative direction. He stated, "This program marks a significant milestone in our innovative approach to treating critical conditions like sepsis, ARDS, AKI, and AHF. By combining AI-driven diagnostics with targeted therapeutics, we're identifying which patients will benefit most from specific interventions, moving beyond one-size-fits-all protocols to deliver personalized care."

Recognition and Future Vision

With these advancements, Prenosis continues to build on its reputation and has received multiple innovation awards from organizations like Chicago Innovation, TIME, and Fast Company for the Sepsis ImmunoScore. Additionally, they have entered into a commercial distribution agreement with Roche, highlighting a strong collaborative future ahead.

As this Chicago-based tech company progresses, it remains committed to redefining healthcare standards for critical conditions. By harnessing AI and data analytics, Prenosis aims to not just improve diagnosis but also tailor treatment uniquely to each patient’s biological profile, truly embodying a patient-focused approach in healthcare.

For more details on Prenosis and their ongoing projects, visit their official website at prenosis.com or connect with them on LinkedIn.